Disruptions in lipid metabolism, common among NASH patients, lead to the accumulation of various lipids like TC and TGs, alongside increased levels of ALT and AST in the liver, exacerbating liver damage and elevating the risk of cardiovascular diseases, particularly in individuals with T2DM and NAFLD [121,122]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.